Harvard team fingers missing protein as a key to Alzheimer's

Alzheimer's research has long been one of the most high-risk arenas in the drug R&D world. One of the most perplexing issues in the field is that while concentrations of a toxic protein are found in the brains of people with the disease, the same concentrations are also seen in people who don't get Alzheimer's. Now a group of scientists at Harvard say they may have found the reason why. The team concluded that a protein called REST--particularly active in the brains of fetuses and now emerging as a key gene regulator in older brains--also appears to protect neurons in the elderly. And they're in particularly short supply in victims of Alzheimer's. The work suggests a new route for researchers in the field looking to advance new therapies for millions of patients. Story

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.